Related Publications
New Drugs, New Ideas: Payment Policy Innovations for High-Cost Pharmaceuticals
October 01, 2019Access challenges associated with high-cost pharmaceuticals have jump started discussion of solutions ranging from state-based boards reviewing drug price increases to harnessing Medicare’s purchasing power for “price negotiation” to old-fashioned price-setting. More
How FDA Can Act On E-Cigarettes And Protect The Public Health
September 19, 2019After years of decline, increases in American youth tobacco usage have pushed the tobacco control debate back into the forefront of the public health conversation. Youth tobacco use increased from 2011 to 2018, largely driven by e-cigarette usage, which grew from 1.5% to 20.8% of American high school students, representing an increase of 2.83 million adolescents. Despite extensive evidence that e-cigarette chemicals cause morbidity including immediate, harmful changes in endothelial function in healthy nonsmokers, 72% of teenage e-cigarettes users believe e-cigarettes cause some, little, or no harm. More
FTC Concerns Over Bristol-Myers Deal Raise Questions
August 05, 2019On Jan. 3, 2019, Bristol-Myers Squibb Co. announced its proposed acquisition of Celgene Corp. for approximately $74 billion. The Federal Trade Commission issued requests for additional information and documentary materials to the companies on March 25, 2019, that were “focused on marketed and pipeline products for the treatment of psoriasis.” In order to address the FTC’s concerns, BMS plans to divest Celgene’s Otezla (apremilast) drug, which is a phosphodiesterase-4 inhibitor indicated for the treatment of moderate to severe psoriasis and psoriatic arthritis. Psoriasis is an autoimmune disease with multiple subtypes, with large skin plaques being the most common manifestation. More
Pricing Power And New Prescription Drugs
August 01, 2019The pricing of prescription drugs comes under persistent public scrutiny, yet limited empirical evidence details the determinants of these price levels. This study provides a price function specification for newly launched drugs, with marginal cost and pricing power components.
More